- Home
- Publications
- Publication Search
- Publication Details
Title
Mcl-1 inhibitors: a patent review
Authors
Keywords
-
Journal
EXPERT OPINION ON THERAPEUTIC PATENTS
Volume 27, Issue 2, Pages 163-178
Publisher
Informa UK Limited
Online
2016-10-17
DOI
10.1080/13543776.2017.1249848
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Structural Re-engineering of the α-Helix Mimetic JY-1-106 into Small Molecules: Disruption of the Mcl-1-Bak-BH3 Protein-Protein Interaction with 2,6-Di-Substituted Nicotinates
- (2016) Brandon Drennen et al. ChemMedChem
- Structure-based design of N-substituted 1-hydroxy-4-sulfamoyl-2-naphthoates as selective inhibitors of the Mcl-1 oncoprotein
- (2016) Maryanna E. Lanning et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods
- (2016) Nicholas F. Pelz et al. JOURNAL OF MEDICINAL CHEMISTRY
- Allosteric inhibition of antiapoptotic MCL-1
- (2016) Susan Lee et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Allosteric inhibition of antiapoptotic MCL-1
- (2016) Susan Lee et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Role of Apoptosis in disease
- (2016) B. Favaloro et al. Aging-US
- Discovery of Tricyclic Indoles That Potently Inhibit Mcl-1 Using Fragment-Based Methods and Structure-Based Design
- (2015) Jason P. Burke et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity
- (2015) Milan Bruncko et al. JOURNAL OF MEDICINAL CHEMISTRY
- BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics
- (2015) C Touzeau et al. LEUKEMIA
- Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)
- (2015) J D Leverson et al. Cell Death & Disease
- CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo
- (2015) G P Gregory et al. LEUKEMIA
- Fragment-based discovery of potent inhibitors of the anti-apoptotic MCL-1 protein
- (2014) Andrew M. Petros et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- 3-Substituted-N-(4-Hydroxynaphthalen-1-yl)arylsulfonamides as a Novel Class of Selective Mcl-1 Inhibitors: Structure-Based Design, Synthesis, SAR, and Biological Evaluation
- (2014) Fardokht A. Abulwerdi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker
- (2013) David J. Richard et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Differences in gene expression and cytokine levels between newly diagnosed and chronic pediatric ITP
- (2013) M. Jernas et al. BLOOD
- Discovery of Potent Mcl-1/Bcl-xL Dual Inhibitors by Using a Hybridization Strategy Based on Structural Analysis of Target Proteins
- (2013) Yuta Tanaka et al. JOURNAL OF MEDICINAL CHEMISTRY
- The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein–protein interactions with Bak
- (2013) Xiaobo Cao et al. Molecular Cancer
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML
- (2012) Thanh-Trang Vo et al. CELL
- A Competitive Stapled Peptide Screen Identifies a Selective Small Molecule that Overcomes MCL-1-Dependent Leukemia Cell Survival
- (2012) Nicole A. Cohen et al. CHEMISTRY & BIOLOGY
- Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
- (2012) C. M. Rudin et al. CLINICAL CANCER RESEARCH
- Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia
- (2012) S. P. Glaser et al. GENES & DEVELOPMENT
- Discovery of Potent Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods and Structure-Based Design
- (2012) Anders Friberg et al. JOURNAL OF MEDICINAL CHEMISTRY
- Clonal evolution in cancer
- (2012) Mel Greaves et al. NATURE
- Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review
- (2011) Naval Bajwa et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
- (2011) Leena Gandhi et al. JOURNAL OF CLINICAL ONCOLOGY
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7
- (2011) Ingrid E. Wertz et al. NATURE
- Predictive biomarkers: a paradigm shift towards personalized cancer medicine
- (2011) Nicholas B. La Thangue et al. Nature Reviews Clinical Oncology
- Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy
- (2011) T. N. Chonghaile et al. SCIENCE
- The cyclin-dependent kinase inhibitor R-roscovitine down-regulates Mcl-1 to override pro-inflammatory signalling and drive neutrophil apoptosis
- (2010) Andrew E. Leitch et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
- (2010) Wyndham H Wilson et al. LANCET ONCOLOGY
- The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer
- (2010) Michelle L Stewart et al. Nature Chemical Biology
- Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines
- (2010) H Zhang et al. ONCOGENE
- Use of Human Cancer Cell Lines Mitochondria to Explore the Mechanisms of BH3 Peptides and ABT-737-Induced Mitochondrial Membrane Permeabilization
- (2010) Nelly Buron et al. PLoS One
- Control of mitochondrial apoptosis by the Bcl-2 family
- (2009) J. K. Brunelle et al. JOURNAL OF CELL SCIENCE
- The Bcl-2 Homology Domain 3 Mimetic ABT-737 Targets the Apoptotic Machinery in Acute Lymphoblastic Leukemia Resulting in Synergistic in Vitro and in Vivo Interactions with Established Drugs
- (2009) L. M. High et al. MOLECULAR PHARMACOLOGY
- RNA Silencing of Mcl-1 Enhances ABT-737-Mediated Apoptosis in Melanoma: Role for a Caspase-8-Dependent Pathway
- (2009) Angela M. Keuling et al. PLoS One
- Inducing apoptosis and enhancing chemosensitivity to Gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell
- (2008) San-Hua Wei et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- Mcl-1 is a potential therapeutic target in multiple types of cancer
- (2008) C. Akgul CELLULAR AND MOLECULAR LIFE SCIENCES
- Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models
- (2008) A. R. Shoemaker et al. CLINICAL CANCER RESEARCH
- Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein–protein interaction
- (2008) Michael D Wendt Expert Opinion on Drug Discovery
- Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins
- (2008) Cheol-Min Park et al. JOURNAL OF MEDICINAL CHEMISTRY
- Down-Regulation of Mcl-1 by Small Interfering RNA Sensitizes Resistant Melanoma Cells to Fas-Mediated Apoptosis
- (2008) N. Chetoui et al. MOLECULAR CANCER RESEARCH
- Bcl-2 family proteins and cancer
- (2008) K W Yip et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now